在捷克共和国28个糖尿病科，对2型糖尿病患者在当前治疗基础上加用艾塞那肽（百泌达）后体重及糖尿病控制情况（糖化血红蛋白）的变化——BIBYII研究（为期24个月的观察）

[Changes in weight and diabetes compensation (HbA1c) in patients with diabetes mellitus type 2 after adding exenatide (Byetta) to the current treatment in 28 diabetology departments in the Czech Republic - BIBYII study (observations lasting 24 months)].

作者信息

Perušičová J, Piťhová P, Haladová I, Diabetologů A Pracovní Skupina, Acsová D, Bělobrádková J, Belzová A, Berková K, Doležalová B, Dvořáková H, Hejnicová K, Hudcová M, Kallmünzerová D, Krejsová Z, Markofová G, Müllerová H, Owen K, Pelikánová M, Raclavská L, Račická E, Skarpová O, Váchová A, Veselá A, Vyoralová J, Brož J, Edelsberger T, Honka M, Hrdina T, Chmura P, Tosovsky J

机构信息

Interni Klinika, Lekarske Fakulty UK a FN Motol, Praha.

出版信息

Vnitr Lek. 2013 Apr;59(4):249-55.

PMID:23711049

Abstract

UNLABELLED

BIBYII STUDY OBJECTIVE: To obtain experience with longterm (24 months) exenatide treatment (Byetta) in patients with diabetes mellitus type 2 from a common clinical practice of diabetology departments in the Czech Republic. TYPE OF OBSERVATION: Observational study conducted by a randomly selected group of outpatient medical practitioners from 28 diabetology departments in the Czech Republic. OBSERVED AND ASSESSED POPULATION: From the original population of 465 patients, who underwent a minimum of three months Byetta treatment, 169 patients (36.6%) remained during the second prolonged observation after 18 months, and 76 patients completed 24 months of uninterrupted Byetta treatment. The following basic information about the patients was collected: year of birth, sex, age when diabetes mellitus (DM) manifested, height, maximum weight before diabetes and when DM manifested. The study recorded the following values in three- month intervals: weight, waistline, glycated haemoglobin (HbA1c), and DM treatment. The population of the prolonged observation comprised 50.3% women and 49.7 % men, and the average age at the time of DM2 manifestation was 48.0 (20- 73 years).

RESULTS

At the beginning of Byetta treatment, the average maximum BMI in the subpopulation observed for 24 months was 38.44; after 3, 6, 9, 12 and 24 months the following levels were measured, respectively: 36.79, 36.22, 35.91, 35.57 and 35.58. The original HbA1c level of 7.44% at the beginning of Byetta treatment decreased after 3, 6, 9, 12 and 24 months to 6.33, 5.98, 5.83, 5.86 and 5.93%.

CONCLUSION

Adding Byetta to the currently applied treatment of obese patients with diabetes mellitus type 2 over a period of 24 months has led to an improvement in HbA1c level by 1.51%, and BMI level was reduced by 2.37 after two years of Byetta treatment.

摘要

未标记

BIBYII研究

目的

从捷克共和国糖尿病科的普通临床实践中获取2型糖尿病患者使用长效（24个月）艾塞那肽治疗（百泌达）的经验。

观察类型

由捷克共和国28个糖尿病科随机挑选的一组门诊医生进行的观察性研究。

观察和评估人群

在最初的465例接受至少三个月百泌达治疗的患者中，169例患者（36.6%）在18个月后的第二次延长观察期仍在治疗，76例患者完成了24个月不间断的百泌达治疗。收集了患者的以下基本信息：出生年份、性别、糖尿病（DM）发病时的年龄、身高、糖尿病发病前及发病时的最大体重。该研究每三个月记录一次以下数值：体重、腰围、糖化血红蛋白（HbA1c）和糖尿病治疗情况。延长观察期的人群中女性占50.3%，男性占49.7%，2型糖尿病发病时的平均年龄为48.0岁（20 - 73岁）。

结果

在百泌达治疗开始时，接受24个月观察的亚组人群的平均最大体重指数为38.44；在3、6、9、12和24个月后分别测量到以下数值：36.79、36.22、35.91、35.57和35.58。百泌达治疗开始时HbA1c的初始水平为7.44%，在3、6、9、12和24个月后分别降至6.33%、5.98%、5.83%、5.86%和5.93%。